Klin Farmakol Farm. 2008;22(4):153-155
Vaccination against HPV
- Onkogynekologické centrum, Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha
Cervical cancer ranks second in deaths from cancer among women worldwide. Persistent high risk HPV infection has been strongly linked to causing cervical carcinoma. Prophylactic vaccines are targeted to prevent the infection caused by most common high risk genotypes of HPV – 16 and 18, which are associated with approximately 70% of cervical cancers. Seroconversion was seen in 100% of cases after administration of all three doses. Seroconversion is independent of age and HPV DNA status at the entry. Detection of high level of specific antibodies is determined by adjuvant system included in vaccine. Both vaccines show 100% efficacy against lesions associated with HPV 16 and 18. In addition, quadrivalent vaccine is targeted to prevent HPV 6 and 11 – main etiological agents of benign genital warts. However, bivalent vaccine shows cross protection against another high risk genotypes HPV – 45 and 31. Vaccines shows excelent safety profile and all described adverse events are not usually serious.
Keywords: Key words: prophylactic vaccine, human papillomavirus, cervical cancer.
Published: January 1, 2009 Show citation
References
- Prendiville W, Davies P. The health professional ´s HPV handbook. Abingdon, Taylor and Francis 2004.
- Sláma J, Freitag P. Vakcíny proti lidským papilomavirům. Prakt Gynekol 2007; 1: 30-32.
- Harper DM. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 2008; 5: 313-324.
Go to original source... - Mohdavi A, Monk BJ. Vaccines agains human papillomavirus and cervical cancer: Promises and challenges. Onkologist 2007; 10: 528-538. Go to original source...
- Sláma J. Prekancerózy v gynekologii. Modern Gynek Porod 2007; 16: 462-487.
- Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765. Go to original source...
Go to PubMed... - Villa LL, Costa RL, Petta CA, et al. Prophyllactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278. Go to original source... Go to PubMed...
- Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257. Go to original source... Go to PubMed...
- Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from randomised control trial. Lancet 2006; 367: 1247-1255. Go to original source... Go to PubMed...
- Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophyllactic quadrivalent human papillomavirus types 6, 11, 16 and 18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-1466. Go to original source... Go to PubMed...
- Chlíbek R. Imunogenita vakcín proti lidskému papilomaviru. Vakcinologie 2008; 2: 145-153.
- Jenkins D. A review of cross-protection against oncogenic HPV by an HPV - 16/18 AS04-adjuvated cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110: 18-25. Go to original source... Go to PubMed...
- Sláma J, Freitag P, Cibula D, Fischrová D, Janoušek M, Pavlišta D, Strunová M, Zikán M, Jančárková N. Adenoprekancerózy děložního hrdla. Čes Gynekol 2006; 71: 446-450.